#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Herpes simplex Arrhythmia Barth syndrome Congenital hypotransferrinaemia Cutaneous T-cell lymphoma recurrent Palmar-plantar erythrodysaesthesia syndrome Pneumonia Macular telangiectasia Prader-Willi syndrome Glomerulonephritis rapidly progressive Langerhans' cell histiocytosis Congenital aplastic anaemia Central nervous system lymphoma Loss of consciousness Cutaneous T-cell lymphoma stage II More trials…

    Learn about Rare Diseases

    Primary biliary cholangitis – Trials in Disease Glomerulonephritis membranoproliferative – Trials in Disease Systemic sclerosis pulmonary – Life with Disease Chondrosarcoma metastatic – Trials in Disease Pleomorphic leiomyosarcoma – Life with Disease Optic glioma – Basic Information Prolymphocytic leukaemia – Trials in Disease Cystic fibrosis lung – Treatment Progressive multifocal leukoencephalopathy – Treatment Cerebral arteriovenous malformation haemorrhagic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rezafungin Acetate MZE829 Vindesine Sulfate Ag-946 Phosphate Gliquidone Baxdrostat Lbl-007 Epinephrine Bitartrate Formoterol Fumarate Dihydrate Siponimod RO7837195 Abt-494 Quinine Dihydrochloride Docetaxel Belzutifan Dexamethasone Acetate Bi 1291583 Celecoxib Avb-101 Enfuvirtide More therapies…

    Learn about Your Condition

    Mitral valve prolapse Oesophageal disorder Infertility female Dry mouth Salivary gland cancer Trisomy 21 Bronchitis Mitral valve disease Colorectal cancer stage IV Vaginal cancer Nephrolithiasis Arterial disorder Bartonellosis Non-Hodgkin's lymphoma Melanoma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Johanniter GmbH Johanniter-Krankenhaus

Johanniter GmbH Johanniter-Krankenhaus

Johanniterstrasse 3-5, Zentrum, Bonn, 53113, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    France Germany Italy Spain

  • Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Dexamethasone
    • Isatuximab
    Germany

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage I
    • Breast cancer male
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Ireland Spain

  • Study on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Extranodal marginal zone B-cell lymphoma (MALT type)
    • Splenic marginal zone lymphoma
    • Nodal marginal zone B-cell lymphoma
    Investigated Drugs:
    • Copanlisib Dihydrochloride
    • Rituximab
    Germany

  • Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carfilzomib
    • Isatuximab
    • Lenalidomide
    Germany

  • Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Ribociclib
    Germany

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Procarbazine Hydrochloride
    • Dacarbazine
    • Brentuximab Vedotin
    Austria Denmark Germany The Netherlands Norway Sweden

  • Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Bortezomib
    • Isatuximab
    Austria Germany

  • Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Volrustomig
    • Carboplatin
    • Infliximab
    Austria Belgium Czechia France Germany Hungary +5
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!